Searched for: subject:"Animals"
(1 - 20 of 22)

Pages

document
van der Hoorn, J.W.A. (author), Jukema, J.W. (author), Havekes, L.M. (author), Lundholm, E. (author), Camejo, G. (author), Rensen, P.C.N. (author), Princen, H.M.G. (author), TNO Kwaliteit van Leven (author)
Background and purpose: We have evaluated the effects of a peroxisome proliferator-activated receptor (PPAR)α/γ agonist on the progression of pre-existing atherosclerotic lesions in APOE*3Leiden.cholesteryl ester transfer protein (E3L.CETP) transgenic mice. Experimental approach: E3L.CETP mice were fed a high-cholesterol diet for 11 weeks to...
article 2009
document
de Ruiter, M.C. (author), Alkemade, F.E. (author), de Gittenberger - Groot, A.C. (author), Poelmann, R.E. (author), Havekes, L.M. (author), van Dijk, K.W. (author), TNO Kwaliteit van Leven (author)
In this review, we briefly summarize the possible signals crossing the placental barrier and discuss the molecular mechanisms of epigenetic programming in the developing fetus leading to increased athero-susceptibility of the vessel wall. © 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins.
article 2008
document
van der Hoorn, J.W.A. (author), de Haan, W. (author), Berbée, J.P.P. (author), Havekes, L.M. (author), Jukema, J.W. (author), Rensen, P.C. (author), Princen, H.M.G. (author), TNO Kwaliteit van Leven (author)
Objective - Niacin potently decreases plasma triglycerides and LDL-cholesterol. In addition, niacin is the most potent HDL-cholesterol- increasing drug used in the clinic. In the present study, we aimed at elucidation of the mechanism underlying its HDL-raising effect. Methods and Results - InAPOE*3Leiden transgenic mice expressing the human...
article 2008
document
Emeis, J.J. (author), Jirouskova, M. (author), Muchitsch, E.-M. (author), Shet, A.S. (author), Smyth, S.S. (author), Johnson, G.J. (author), TNO Preventie en Gezondheid (author)
Murine blood coagulation factors and function are quite similar to those of humans. Because of this similarity and the adaptability of mice to genetic manipulation, murine coagulation factors and inhibitors have been extensively studied. These studies have provided significant insights into human hemostasis. They have also provided useful...
article 2007
document
Oude Nijhuis, M.M. (author), van Keulen, J.K. (author), Pasterkamp, G. (author), Quax, P.H. (author), de Kleijn, D.P.V. (author), TNO Kwaliteit van Leven (author)
Innate immunity is the first line of defence against invading micro-organisms. The family of Toll-like receptors (TLRs) recognizes pathogen-associated molecular patterns (PAMPs) that are carried by the invading micro-organisms. Infectious pathogens have been implicated to play an important role in atherosclerosis. Nowadays, evidence is...
article 2007
document
Zadelaar, A.S.M. (author), Kleemann, R. (author), Verschuren, L. (author), de Vries-van der Weij, J. (author), van der Hoorn, J. (author), Princen, H.M. (author), Kooistra, T. (author), TNO Kwaliteit van Leven (author)
Atherosclerosis is a multifactorial highly-complex disease with numerous etiologies that work synergistically to promote lesion development. The ability to develop preventive and ameliorative treatments will depend on animal models that mimic the human subject metabolically and pathophysiologically and will develop lesions comparable to those in...
article 2007
document
TNO Kwaliteit van Leven (author), van der Hoorn, J.W.A. (author), Kleemann, R. (author), Havekes, L.M. (author), Kooistra, T. (author), Princen, H.M.G. (author), Jukema, J.W. (author)
AIM: This study was designed to investigate the effect of the angiotensin II receptor blocker olmesartan alone, or in combination with standard treatment with a statin, pravastatin, on atherosclerosis development in APOE*3Leiden transgenic mice. METHODS AND RESULTS: Four groups of 15 mice received an atherogenic diet alone (plasma cholesterol 17...
article 2007
document
TNO Kwaliteit van Leven (author), Alkemade, F.E. (author), de Gittenberger-Groot, A.C. (author), Schiel, A.E. (author), van Munsteren, J.C. (author), Hogers, B. (author), van Vliet, L.S.J. (author), Poelmann, R.E. (author), Havekes, L.M. (author), van Dijk, K.W. (author), de Ruiter, M.C. (author)
OBJECTIVE - Maternal hypercholesterolemia is associated with a higher incidence and faster progression of atherosclerotic lesions in neonatal offspring. We aimed to determine whether an in utero environment exposing a fetus to maternal hypercholesterolemia and associated risk factors can prime the murine vessel wall to accelerated development of...
article 2007
document
Pires, N.M.M. (author), Jukema, J.W. (author), Daemen, M.J.A.P. (author), Quax, P.H.A. (author), TNO Kwaliteit van Leven (author)
In 2001, the first human study with drug-eluting stents (DES) was published showing a nearly complete abolition of restenosis by using a sirolimus-eluting stent. This success was very encouraging to test new compounds in combination with the DES platform. Nevertheless, several other anti-restenotic compounds have been used in human clinical...
article 2006
document
Westerterp, M. (author), van der Hoogt, C.C. (author), de Haan, W. (author), Offerman, E.H. (author), Dallinga-Thie, G.M. (author), Jukema, J.W. (author), Havekes, L.M. (author), Rensen, P.C.N. (author), TNO Kwaliteit van Leven (author)
OBJECTIVE - The role of cholesteryl ester transfer protein (CETP) in the development of atherosclerosis is still undergoing debate. Therefore, we evaluated the effect of human CETP expression on atherosclerosis in APOE*3-Leiden (E3L) mice with a humanized lipoprotein profile. METHODS AND RESULTS - E3L mice were crossbred with human CETP...
article 2006
document
Schepers, A. (author), de Vries, M.R. (author), van Leuven, C.J. (author), Grimbergen, J.M. (author), Holers, V.M. (author), Daha, M.R. (author), van Bockel, J.H. (author), Quax, P.H.A. (author), TNO Kwaliteit van Leven (author)
BACKGROUND - Venous bypass grafts may fail because of development of intimal hyperplasia and accelerated atherosclerosis. Inflammation plays a major role in these processes. Complement is an important part of the immune system and participates in the regulation of inflammation. The exact role of complement in the process of accelerated...
article 2006
document
Schepers, A. (author), Pires, N.M.M. (author), Eefting, D. (author), de Vries, M.R. (author), van Bokel, J.H. (author), Quax, P.H.A. (author), TNO Kwaliteit van Leven (author)
Objective: The aim of this study was to assess whether the anti-inflammatory agent dexamethasone can inhibit vein graft thickening without the occurrence of serious side effects. Methods: Venous interposition grafting was performed in the common carotid artery of hypercholesterolemic ApoE3Leiden transgenic mice. Mice were treated with...
article 2006
document
Schepers, A. (author), Eefting, D. (author), Bonta, P.I. (author), Grimbergen, J.M. (author), de Vries, M.R. (author), van Weel, V. (author), de Vries, C.J. (author), Egashira, K. (author), van Bockel, J.H. (author), Quax, P.H.A. (author), TNO Kwaliteit van Leven (author)
OBJECTIVE - Because late vein graft failure is caused by intimal hyperplasia (IH) and accelerated atherosclerosis, and these processes are thought to be inflammation driven, influx of monocytes is one of the first phenomena seen in IH, we would like to provide direct evidence for a role of the MCP-1 pathway in the development of vein graft...
article 2006
document
Rensen, P.C.N. (author), Havekes, L.M. (author), TNO Kwaliteit van Leven (author)
Chemicals / CAS: 2 methylpropanethioic acid s [2 [1 (2 ethylbutyl)cyclohexylcarboxamido]phenyl] ester, 211513-37-0; atorvastatin, 134523-00-5, 134523-03-8; nicotinic acid, 54-86-4, 59-67-6; torcetrapib, 262352-17-0; Carrier Proteins; CETP protein, human; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Glycoproteins;...
article 2006
document
Trion, A. (author), de Maat, M.P.M. (author), Jukema, J.W. (author), van der Laarse, A. (author), Maas, M.C. (author), Offerman, E.H. (author), Havekes, L.M. (author), Szalai, A.J. (author), Princen, H.M.G. (author), Emeis, J.J. (author), TNO Kwaliteit van Leven (author)
Objective - C-reactive protein (CRP) has been associated with risk of cardiovascular disease. It is not clear whether CRP is causally involved in the development of atherosclerosis. Mouse CRP is not expressed at high levels under normal conditions and increases in concentration only several-fold during an acute phase response. Because the...
article 2005
document
Wang, M. (author), Lamers, R.J.A.N. (author), Korthout, H.A.A.J. (author), van Nesselrooij, J.H.J. (author), Witkamp, R.F. (author), van der Heijden, R. (author), Voshol, P.J. (author), Havekes, L.M. (author), Verpoorte, R. (author), van der Greef, J. (author), TNO Kwaliteit van Leven (author)
The introduction of the concept of systems biology, enabling the study of living systems from a holistic perspective based on the profiling of a multitude of biochemical components, opens up a unique and novel opportunity to reinvestigate natural products. In the study of their bioactivity, the necessary reductionistic approach on single active...
article 2005
document
Kleemann, R. (author), Verschuren, L. (author), de Rooij, B.J. (author), Lindeman, J. (author), de Maat, M.M. (author), Szalai, A.J. (author), Princen, H.M.G. (author), Kooistra, T. (author), Gaubius Instituut TNO (author)
Inflammatory processes, aside from cholesterol, play a central role in atherogenesis. Human C-reactive protein (huCRP) signals systemic inflammation and independently predicts future cardiovascular risk. Cholesterol-lowering statins reduce atherosclerosis and plasma huCRP levels. Evidence is sought for a direct anti-inflammatory statin effect in...
article 2004
document
de Maat, M.P.M. (author), Trion, A. (author), TNO Preventie en Gezondheid (author)
Purpose of review C-reactive protein (CRP) is consistently associated with cardiovascular disease in prospective and cross-sectional clinical and epidemiological studies. Inflammation is an important mechanism in cardiovascular disease, and the plasma level of CRP is considered to. reflect the inflammatory condition of the patient and/or the...
article 2004
document
van Eck, M. (author), Herijgers, N. (author), van Dijk, K.W. (author), Havekes, L.M. (author), Hofker, M.H. (author), Groot, P.H.E. (author), van Berkel, T.J.C. (author), Gaubius Instituut TNO (author)
The effect of monocyte/macrophage-derived wild-type mouse apolipoprotein E (apoE), human apoE3-Leiden, and human apoE2 on serum cholesterol levels and the development of atherosclerosis in apoE-deficient (apoe-/-) mice was investigated by using bone marrow transplantation (BMT). At 4 weeks after BMT, murine apoe+/+ bone marrow reduced serum...
article 2000
document
de Winther, M.P.J. (author), Gijbels, M.J.J. (author), van Dijk, K.W. (author), van Gorp, P.J.J. (author), Suzuki, H. (author), Kodama, T. (author), Frants, R.R. (author), Havekes, L.M. (author), Hofker, M.H. (author), Gaubius instituut TNO (author)
Apolipoprotein (apo) E3Leiden is a dysfunctional apo E variant associated with familial dysbetalipoproteinemia in humans. Transgenic mice carrying the APOE3Leiden gene develop hyperlipidemia and are highly susceptible to diet-induced atherosclerosis. An early step in atherosclerosis is foam cell formation, which is thought to result from the...
article 1999
Searched for: subject:"Animals"
(1 - 20 of 22)

Pages